Canaccord Genuity provided 24/7 Wall St. with a research note on its downgrade of Dendreon (NASDAQ: DNDN):
DNDN Target Cut
Following Dendreon’s (DNDN) Q2 2012 results Canaccord Genuity biotechnology analyst Salveen Richter lowered her price target on the company to $6 from $11. Ms. Richter said:
“We would hope that the new sales force and nursing field team hires coming on board in July and August enable a reacceleration in growth (management expects an impact in 1Q13). Nevertheless, we are lowering our peak U.S. Provenge revenue to $594M in FY16 vs. $728M prior and remain on the sidelines due to limited visibility on an improvement in same- store sales, execution and competitive dynamics.”
Ms. Richter had no change to her HOLD rating on the company.
For disclosures about any company mentioned click here.
For corporate disclosures click here.
Douglas A. McIntyre
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
